Fig. 3From: Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in CanadaProbabilistic sensitivity analysis incremental cost-effectiveness scatterplot—Scatterplot showing the 95% confidence ellipse comparing the incremental cost-effectiveness of omalizumab compared to dupilumab at a Willingness-to-pay threshold of $50,000, b Willingness-to-pay threshold of $100,000, and c Willingness-to-pay threshold of $150,000Back to article page